Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity-Reference-Cited by-同舟云学术

Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity

Published:2023-10-26 Issue:3 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Connors Jennifer¹²^ORCID,Cusimano Gina¹²^ORCID,Mege Nathan³^ORCID,Woloszczuk Kyra¹²,Konopka Emily¹²,Bell Matthew¹²^ORCID,Joyner David²⁴,Marcy Jennifer⁴,Tardif Virginie²^ORCID,Kutzler Michele A.¹²^ORCID,Muir Roshell²⁵^ORCID,Haddad Elias K.¹²^ORCID

Affiliation:

1. Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA

2. Department of Medicine, Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA, USA

3. Tower Health, Reading Hospital, West Reading, PA, USA

4. Department of Molecular and Cellular Biology, Drexel University College of Medicine, Philadelphia, PA, USA

5. Department of Family, Community, and Preventative Medicine, Drexel University College of Medicine, Philadelphia, PA, USA

Funder

no funding associated

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2267295

Reference114 articles.

1. Human immune system variation

2. Advances in microfluidics in combating infectious diseases

3. Systems immunology: just getting started

4. Network approaches to systems biology analysis of complex disease: integrative methods for multi-omics data

5. Multi-omics approaches to disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility of Using a Type I IFN-Based Non-Animal Approach to Predict Vaccine Efficacy and Safety Profiles;Vaccines;2024-05-27

2. Editorial to special issue “The power of immunoprofiling supported by computational data integration and machine learning”;Human Vaccines & Immunotherapeutics;2024-03-15